FDA Approves Subcutaneous Tecentriq Hybreza for All Adult Indications of IV Form of Tecentriq

Subcutaneous Tecentriq Hybreza will provide patients and physicians increased flexibility for administration of the immunotherapy across approved indications for Tecentriq, including non–small cell lung cancer, small cell lung cancer, and hepatocellular carcinoma.